Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis

This review summarizes Phase III clinical trial data available for fingolimod. The main purpose is to evaluate the benefit-risk profile of fingolimod, the first oral compound available for treatment of multiple sclerosis (MS) and just recently approved by the European authorities. The authors place...

Descripción completa

Detalles Bibliográficos
Autores principales: Warnke, Clemens, Stüve, Olaf, Hartung, Hans-Peter, Fogdell-Hahn, Anna, Kieseier, Bernd C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173035/
https://www.ncbi.nlm.nih.gov/pubmed/21931494
http://dx.doi.org/10.2147/NDT.S10481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173035/
https://www.ncbi.nlm.nih.gov/pubmed/21931494
http://dx.doi.org/10.2147/NDT.S10481

Ejemplares similares